Abstract
Prior work in our laboratory has identified putative subtypes of delta (delta cx-1, delta cx-2, delta ncx-1, delta ncx-2) and kappa 2 (kappa 2a and kappa 2b) receptors. Previous studies showed that chronic (three day) i.c.v. administration of antisense oligodeoxynucleotide to the cloned delta opioid receptor selectively decreased [3H][D-Ala2,D-Leu5]enkephalin binding to the delta ncx site, not the delta cx-2 site. The present study extends this work by demonstrating that delta antisense DNA selectively affects the delta ncx-2 site sparing the other putative delta receptor subtypes and kappa 2 receptor subtypes. This selectivity is not due to anatomically specific effects of delta antisense DNA since autoradiograms show that delta binding is reduced in all regions of the brain after chronic i.c.v. administration of delta antisense DNA. These data strongly suggest that the delta cx-1, delta cx-2, delta ncx-1, kappa 2a and kappa 2b binding sites are different proteins than the delta ncx-2 binding site, which, based on its sensitivity to delta antisense DNA, is synonymous to the cloned delta opioid receptor. Viewed collectively, these data suggest that administration of delta antisense DNA, and by extension other receptor-selective...Continue Reading
References
Jun 9, 1977·Nature·J A LordH W Kosterlitz
Jun 5, 1992·European Journal of Pharmacology·M SofuogluA E Takemori
Oct 30, 1992·Journal of Medicinal Chemistry·P S PortogheseA E Takemori
Nov 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·A RichardsonE A Barnard
Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·B L KiefferC G Hirth
Dec 28, 1992·Science·C J EvansR H Edwards
Sep 1, 1992·Peptides·R B RothmanL S Brady
Nov 1, 1992·Peptides·H XuR B Rothman
Mar 1, 1991·Peptides·R B RothmanK C Rice
Jul 1, 1991·Peptides·S DupinJ M Zajac
Jan 1, 1991·Life Sciences·H XuR B Rothman
Sep 1, 1991·Pharmacopsychiatry·T F MeertP A Janssen
Mar 1, 1990·Peptides·R B RothmanL S Brady
Jan 1, 1989·Life Sciences·M S AhmedD Maulik
Jan 16, 1989·Brain Research·L S BradyR B Rothman
Jun 1, 1989·Journal of Medicinal Chemistry·C H KimK C Rice
Jul 1, 1987·Neuropeptides·J SimonM Wollemann
Aug 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·W F SimondsW A Klee
Jun 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·T M ChoH H Loh
Jul 13, 1987·Life Sciences·J SimonK Medzihradszky
May 1, 1984·Neuropeptides·R B RothmanK C Rice
Aug 1, 1981·British Journal of Pharmacology·H W KosterlitzL E Robson
Aug 27, 1981·European Journal of Pharmacology·R QuirionC B Pert
Jan 1, 1995·Trends in Neurosciences·A MansourS J Watson
Aug 1, 1995·Anesthesia and Analgesia·J G D'Alessio
Jan 1, 1995·Peptides·X Y ChaR B Rothman
Jan 1, 1994·Life Sciences·E J BilskyJ Lai
May 9, 1994·Neuroreport·J LaiF Porreca
Nov 1, 1993·Peptides·Q NiR B Rothman
Apr 1, 1994·Neuron·K M StandiferG W Pasternak
Nov 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·J B WangG R Uhl
Sep 1, 1993·Peptides·H XuR B Rothman
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·K YasudaG I Bell
Citations
Apr 4, 1997·European Journal of Pharmacology·L TollJ S Auh
Jan 1, 1997·Journal of Neuroscience Methods·A Nicot, D W Pfaff
Mar 11, 1998·Peptides·H XuR B Rothman
Aug 13, 1998·Peptides·Q NiR B Rothman
Jan 1, 1997·Brain Research Bulletin·S ShahB C Yoburn
Oct 1, 2013·Pharmacological Reviews·Gavril W Pasternak, Ying-Xian Pan